Depleting tumor-specific Tregs at a single site eradicates disseminated tumors A Marabelle, H Kohrt, I Sagiv-Barfi, B Ajami, RC Axtell, G Zhou, ... The Journal of clinical investigation 123 (6), 2447-2463, 2013 | 450 | 2013 |
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK I Sagiv-Barfi, HEK Kohrt, DK Czerwinski, PP Ng, BY Chang, R Levy Proceedings of the National Academy of Sciences 112 (9), E966-E972, 2015 | 438 | 2015 |
Eradication of spontaneous malignancy by local immunotherapy I Sagiv-Barfi, DK Czerwinski, S Levy, IS Alam, AT Mayer, SS Gambhir, ... Science translational medicine 10 (426), eaan4488, 2018 | 366 | 2018 |
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies HE Kohrt, A Thielens, A Marabelle, I Sagiv-Barfi, C Sola, F Chanuc, ... Blood, The Journal of the American Society of Hematology 123 (5), 678-686, 2014 | 308 | 2014 |
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity HE Kohrt, I Sagiv-Barfi, S Rafiq, SEM Herman, JP Butchar, C Cheney, ... Blood, The Journal of the American Society of Hematology 123 (12), 1957-1960, 2014 | 234 | 2014 |
Targeting CD137 enhances the efficacy of cetuximab HE Kohrt, AD Colevas, R Houot, K Weiskopf, MJ Goldstein, P Lund, ... The Journal of clinical investigation 124 (6), 2668-2682, 2014 | 199 | 2014 |
Autologous iPSC-based vaccines elicit anti-tumor responses in vivo NG Kooreman, Y Kim, PE de Almeida, V Termglinchan, S Diecke, ... Cell stem cell 22 (4), 501-513. e7, 2018 | 157 | 2018 |
Imaging activated T cells predicts response to cancer vaccines IS Alam, AT Mayer, I Sagiv-Barfi, K Wang, O Vermesh, DK Czerwinski, ... The Journal of clinical investigation 128 (6), 2569-2580, 2018 | 120 | 2018 |
Treatment using bruton's tyrosine kinase inhibitors and immunotherapy R Levy, B Chang, P Ng, I Sagiv-barfi | 104 | 2015 |
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma I Sagiv-Barfi, HE Kohrt, L Burckhardt, DK Czerwinski, R Levy Blood, The Journal of the American Society of Hematology 125 (13), 2079-2086, 2015 | 84 | 2015 |
An mRNA SARS-CoV-2 vaccine employing charge-altering releasable transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory OAW Haabeth, JJK Lohmeyer, A Sallets, TR Blake, I Sagiv-Barfi, ... ACS Central Science 7 (7), 1191-1204, 2021 | 40 | 2021 |
Radiotherapy and toll-like receptor agonists A Marabelle, A Filatenkov, I Sagiv-Barfi, H Kohrt Seminars in Radiation Oncology 25 (1), 34-39, 2015 | 28 | 2015 |
Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity N Rajasekaran, M Sadaram, J Hebb, I Sagiv-Barfi, S Ambulkar, ... Blood 124 (21), 3118, 2014 | 27 | 2014 |
Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors I Sagiv-Barfi, E Weiss, A Levitzki Bioorganic & medicinal chemistry 18 (17), 6404-6413, 2010 | 26 | 2010 |
Intratumoral immunotherapy relies on B and T cell collaboration I Sagiv-Barfi, DK Czerwinski, T Shree, JJK Lohmeyer, R Levy Science immunology 7 (71), eabn5859, 2022 | 21 | 2022 |
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin … C Chester, S Chang, JF Kurland, I Sagiv-Barfi, D Czerwinski, A Rajapaksa, ... Journal of Clinical Oncology 32 (15_suppl), 3017-3017, 2014 | 20 | 2014 |
Neoadjuvant intratumoral immunotherapy with TLR9 activation and anti-OX40 antibody eradicates metastatic cancer WX Hong, I Sagiv-Barfi, DK Czerwinski, A Sallets, R Levy Cancer research 82 (7), 1396-1408, 2022 | 19 | 2022 |
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression CL Miller, I Sagiv-Barfi, P Neuhöfer, DK Czerwinski, SE Artandi, ... Cell chemical biology 29 (3), 451-462. e8, 2022 | 16 | 2022 |
A color discriminating broad range cell staining technology for early detection of cell transformation. AEAL Idit Sagiv, Pavel Idelevich, Ilia Rivkin, Rimona Margalit Journal of Carcinogenesis, 2009 | 14 | 2009 |
Obinutuzumab (GA101) is less prone to antagonism of immune effector function by ibrutinib than rituximab in vitro and in vivo S Herter, I Sagiv-Barfi, C Chester, M Sadaram, J Hebb, DK Czerwinski, ... Blood 124 (21), 1765, 2014 | 13 | 2014 |